Literature DB >> 7512798

Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases.

A Anstey1, R Cerio, N Ramnarain, G Orchard, N Smith, E W Jones.   

Abstract

Using a panel of seven cell markers, we studied the value of immunocytochemical labelling in the histological diagnosis of desmoplastic malignant melanoma. Sections from routine formalin-fixed tissue of 45 surgical specimens were obtained from 25 cases of malignant melanoma that showed well-marked desmoplastic or neurotropic features. Routinely stained sections (Haematoxylin- and -eosin and melanin stains) were compared with the following panel of seven antibodies: S-100, neuron-specific enolase (NSE), vimentin, factor XIIIa (FXIIIa), desmin and the newer, supposedly more specific antimelanoma antibodies HMB45 and NKIC3. S-100 and NSE were the most sensitive antibodies for desmoplastic malignant melanoma with strong labelling of spindle cells in most cases. In contrast, results for NKIC3 were more variable; results were negative in nearly half the tumours, but strong labelling was seen in six cases (27%). Positive labelling for HMB45 was noted in five tumours (22%); it was mostly confined to small groups of cells in the superficial part of the lesions. Tumour spindle cells were negative for FXIIIa in all cases; there was no increase in the number of positive dermal dendritic cells compared to conventional and spindle cell melanoma. All tumours were desmin-negative, but most were vimentin-positive. Our findings indicate that immunocytochemistry is of less value in the diagnosis of desmoplastic malignant melanoma that it is with other types of malignant melanoma. However, positive or negative labelling for S-100 protein and NSE is useful for suggesting or excluding a diagnosis of desmoplastic malignant melanoma; neither marker is specific and, in particular, positive labelling is also found in most neurofibromas and benign cellular naevi.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512798     DOI: 10.1097/00000372-199402000-00004

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  5 in total

1.  Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.

Authors:  G E Orchard
Journal:  Histochem J       Date:  2000-08

2.  PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.

Authors:  Khadijeh Jahanseir; Deyin Xing; Patricia T Greipp; William R Sukov; Gary L Keeney; Brooke E Howitt; J Kenneth Schoolmeester
Journal:  Int J Gynecol Pathol       Date:  2018-11       Impact factor: 2.762

Review 3.  Neurotropic malignant melanoma presenting as a trigeminal sensory neuropathy.

Authors:  T A Hughes; I N McQueen; A Anstey; P Laidler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

Review 4.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

Review 5.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.